The Effects of Dandelion Polysaccharides on Iron Metabolism by Regulating Hepcidin via JAK/STAT Signaling Pathway

Feng Ren, Yingying Yang, Kaixuan Wu, Tiesuo Zhao, Yinghao Shi, Moxuan Song, and Jian Li

1School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang 453003, China
2School of Nursing, Xinxiang Medical University, Xinxiang 453003, China
3School of Forensic Medicine, Xinxiang Medical University, Xinxiang 453003, China

Correspondence should be addressed to Feng Ren; 1215377283@qq.com and Jian Li; 704876030@qq.com

Received 3 July 2020; Revised 29 November 2020; Accepted 7 December 2020; Published 4 January 2021

1. Introduction

Primary liver cancer is the sixth most common cancer and the third most common cause of cancer-related deaths around the world. Hepatocellular carcinoma (HCC) accounts for 85%-90% of all primary liver cancers, and its overall 5-year survival rate is less than 16% [1, 2]. Iron is an essential component for life, and the homeostasis of iron is precisely governed in mammals. However, accumulating evidence suggest a direct correlation between excess iron burden and increased risk of developing cancer [3–5], especially for HCC [6–8]. Iron chelators are considered as an adjuvant drug in tumor therapy [9–11].

Hepcidin, a central regulator in iron metabolism, is prominently synthesized and secreted in the liver. Ferroportin, the only known exporter of intracellular iron, is the receptor of hepcidin. Hepcidin binds and induces degradation of ferroportin and inhibits iron absorption from the duodenum, iron release from macrophages, and stored iron egress from hepatocytes [12, 13]. High expression of hepcidin was found in tumor tissues rather than in adjacent nontumor tissues, which was confirmed to be associated with carcinogenesis and tumor development [4, 14–17]. The JAK/STAT signaling pathway plays crucial roles in many cell progresses, including cell proliferation and immune response. Many studies have reported that JAK/STAT signaling is aberrantly activated in HCC and activated JAK/STAT pathway causes dysregulation of its many downstream target genes correlated with proliferation, immune, invasion, and metastasis [18, 19]. In addition, hepcidin activates the JAK/STAT pathway through Jak2 activation and transcription factor Stat3 phosphorylation [20].
Dandelion is a traditional Chinese medicinal herb belonging to the Asteraceae family and is widely used as a diuretic, anti-inflammatory, and antioxidant compound \cite{21, 22}. However, the anticancer effects and the underlying mechanisms of dandelion polysaccharides (DP) on HCC via affecting iron metabolism remain unknown.

A growing body of evidence has suggested that dandelion possessed anticancer effects against breast cancers, gastric cancers, and prostate cancers \cite{23–25}. In our previous research, we showed that dandelion polysaccharide (DP) markedly inhibited the proliferation and growth of HCC cancer cells \cite{26}. Presently, we discovered that DP decreased iron burden in tumor tissues of Hepa1-6 and H22 tumor-bearing mice and hepatoma cancer cells. Moreover, DP could regulate hepcidin expression in vitro and in vivo via inhibiting the phosphorylation of JAK2 and STAT3. Taken together, our data demonstrated that DP suppressed HCC growth through regulating the expression of hepcidin by inhibiting the activity of the JAK/STAT signaling pathway.

2. Materials and Methods

2.1. Cell Lines and Cell Culture. Human hepatocellular carcinoma HepG2 and Huh7 cell lines were purchased from Stem Cell Bank of Chinese Academy of Sciences. Mouse hepatocellular carcinoma Hepa1-6 and H22 cells were obtained from China Center for Type Culture Collection. All cells mentioned above were maintained at 37°C and incubated in 5% CO2. All cells were cultured in DMEM (HyClone, Logan, USA) supplemented with 10% fetal bovine serum (HyClone, Logan, USA). DP with purity of >98% was obtained from Ci Yuan Biotechnology Co., Ltd. Shanxi (Xian, China). For our experiments, HepG2 and Huh7 cells were treated at an increasing concentration of DP (0, 100, 200, or 400 mg/L) on different time points (0, 24, 48, 72, or 96 h). The optimal induction concentration and time of DP for decreasing hepcidin expression were determined.

2.2. Animals and Treatment. Balb/C mice were obtained from Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). The mice were subcutaneously injected with Hepa1-6 cells or H22 cells (2 × 10^6 cells per mouse) and randomly separated into two groups: the control group and the DP group. The DP group was i.p. injected with 200 mg/kg of DP once daily for 14 days \cite{26}. The control group was treated with 0.9% saline via intraperitoneal injection. At last, the liver and tumor of mice were harvested for further analysis. The procedures were approved by the Animal Care Committee of Xinxiang Medical University.

2.3. RT-PCR Analysis. The total RNA of cells was isolated with TRIzol (Invitrogen, Carlsbad, USA). cDNA was
synthesized using Prime-Script™ RT Master Mix according to the supplier’s protocol. The mRNA expression was quantified by using RT-PCR analysis with SYBR Green qPCR master mix (Qiagen, Hilden, Germany). The primers for quantifying hepcidin were 5′-cctgaccagtgctctgttt-3′ and 5′-cacatcccacactttgatcg-3′. The primers for quantifying GAPDH were 5′-aatcccatcaccatcttcca-3′ and 5′-cctgcttcacccatcttg-3′.

2.4. RNA Sequencing and Bioinformatics Analysis. We conducted RNA sequencing for HepG2 cells treated with DP (200 mg/L, 48 h) and their control samples on BGISEQ-500 sequencing platform. Bowtie 2 and RSEM were separately used to map the clean reads to reference the transcripts and calculate the gene expression level for each sample. The RNA-seq expression levels were normalized using the Fragments Per Kilobase of transcript per Million mapped reads. We used DESeq algorithms to detect the differentially expressed genes (DEGs), and the genes that were differentially expressed in HepG2 cells treated with DP and their control samples with q value < 0.001 were selected as DEGs. Pathway enrichment analysis for DEGs was conducted using a web server, KOBASES V3.0.

2.5. Western Blotting. Cells were lysed with RIPA lysis buffer. Tumor tissue samples were pelleted on ice. Protein lysates were subjected to western blot according to the method described previously [26]. All primary antibodies in the present study were listed as follows: hepcidin (Abcam, Cambridge, UK); STAT3, p-STAT3, JAK2, and p-JAK2 (CST, Beverly, USA); and β-actin (Santa Cruz, USA).

2.6. Measurement of Intracellular Iron. The intracellular labile iron pool (LIP) was determined using a fluorescence technique with Fe sensor calcein. The HepG2 and Huh7 cells were cultured on coverslips and treated with DP at a concentration of 200 mg/L for 48 hours. Then, the cells were washed and incubated with 50 μM calcein-AM (Sigma-Aldrich) for 30 min at 37°C. The excess calcein-AM was washed off with PBS. The immunofluorescent signals were detected by using a fluorescence microscope (λex = 490 nm, λem = 515 nm) (Leica Microsystems, Wetzlar, Germany). The calcein-AM fluorescence was quenched by intracellular iron.
2.7. **Immunoﬂuorescence (IF).** HepG2 and Huh7 cells were ﬁxed with 4% paraformaldehyde at 4°C for 10 min and incubated in 0.3% Triton for 30 min. After blocking with 5% goat serum for 30 min at room temperature, the cells were incubated with anti-hepcidin (Abcam, Cambridge, UK) overnight at 4°C, and then, cells were incubated with secondary antibody (Proteintech, USA) for 2 h. DAPI was used to stain the nucleus. The immunoﬂuorescent signals were detected by a ﬂuorescence microscope (Leica Microsystems, Wetzlar, Germany).

2.8. **Prussian Blue Staining.** Prussian blue staining was used to detect iron depositions in tumors. The tumor tissues were incubated in Perls’ reagent with 5% potassium ferrocyanide and 5% hydrochloric acid for 15 min at room temperature. Images of the tissues were captured using a Nikon microscope.

2.9. **Immunohistochemistry.** Approximately 3 μm thick liver sections were incubated with anti-hepcidin (Abcam, Cambridge, UK) overnight at 4°C. After washing with PBS, the
sections were incubated with the secondary antibodies at room temperature for 2 hours.

2.10. Statistical Analysis. The data were shown as the mean ± SD. The groups were compared by one-way analysis of variance, and LSD t-test was utilized for multiple comparisons using SPSS 21.0 (IBM SPSS for Windows, Version 21.0; IBM Corporation, Armonk, NY, USA). P < 0.05 was considered significant.

3. Results

3.1. DP Regulates Iron Burden in Hepatoma Cells and Grafted Tumors. To evaluate the effect of DP in regulating iron content, the intracellular LIP of hepatoma cells was determined using calcein-AM assay. The HepG2 and Huh7 cells were selected and treated with 200 mg/L DP or vehicle for 48 hours. As shown in Figures 1(a) and 1(b), the DP significantly decreased labile iron in HepG2 and Huh7 cells compared with the DMSO control groups (P < 0.01).
Prussian blue staining was performed to detect the iron depositions in tumor tissues of mice. Mice bearing established Hepa1-6 or H22 tumors were randomly separated into 2 groups separately, including the DP group (treated with DP for 14 days) and vehicle (0.9% saline). As demonstrated in Figure 1(c), the accumulation of tissue iron (the arrow) was ameliorated in the tumor sections derived from the DP-treated mice compared with the control group.

3.2. Hepcidin Is Upregulated in HCC. We assayed the expression level of hepcidin in HCC using the GSE57957 dataset. The results confirmed that the expression of hepcidin in tumor tissues was higher than that in the adjacent nontumor tissues from 37 pairs of HCC samples (Figures 2(a) and 2(b)). Moreover, we discovered a higher positive rate of hepcidin in HCC tumor tissues on the basis of IHC staining (Figures 2(c) and 2(d)).

3.3. DP Decreases Hepcidin Level In Vitro. To investigate whether DP decreases the expression of hepcidin, the master regulator of iron homeostasis, we firstly evaluated the effects of DP on hepcidin gene expression in HepG2 and Huh7 cells. The RT-PCR result showed that DP significantly reduced the expression of hepcidin mRNA level in cells incubated with 200 and 400 mg/L DP for 48 h (Figures 3(a) and 3(b)). Next, we examined the time course of the effects of 200 mg/L DP on hepcidin expression. The results suggested that the decreased peak point of hepcidin mRNA in HepG2 and Huh7 cells was at 48 h (Figures 3(c) and 3(d)). The protein levels of hepcidin in HepG2 and Huh7 cells were tested upon the treatment of DP (200 mg/L) for 48 h. Similar to the RT-PCR result, western blot analysis and IF staining also verified that hepcidin protein level was markedly reduced by DP treatment (Figures 3(e) and 3(f)).

3.4. DP Decreases the Expression of Hepcidin In Vivo. To further study the effect of DP on hepcidin expression in vivo, the Balb/C mice bearing established Hepa1-6 and H22 tumors were i.p. injected with DP at a dose of 200 mg/kg per day for 14 days. The protein level of hepcidin in mouse liver was measured by western blot and IHC. Our results indicated that the hepcidin protein level was significantly reduced compared with that in the control group (Figures 4(a) and 4(b)). These results revealed that DP administration could effectively downregulate hepcidin level in vitro and in vivo.

3.5. DP Regulates Hepcidin Expression via the JAK/STAT Pathways In Vitro. To determine the effect of DP on hepcidin expression, RNA-seq was conducted to detect the expression of DP on the transcriptomic profile in HepG2 cells. Pathway analysis showed that DP treatment altered several signaling pathways, including PI3K/AKT, JAK-STAT, MAPK, and HIF-1 pathways (Figure 5(a)). As we know, the JAK/STAT signaling pathway is important for the transcription of hepcidin. Therefore, we analyzed the expression of key factors involved in the pathway in HepG2 cells after DP treatment. Our results showed that the expression of p-JAK2 and p-STAT3 was significantly decreased in the DP group compared with the control group. However, pretreatment with 20 ng/mL of interleukin 6 (IL-6) (a specific activator of STAT3) resulted in a significant increase in the expression of p-JAK2 and p-STAT3 proteins (Figure 5(b)).

Collectively, these results shown here indicated that DP inhibited the expression of hepcidin by targeting IL-6-induced JAK/STAT signaling pathways in vitro.

4. Discussion

The liver is the major organ for iron storage in the human body. Clinical studies have indicated that intrathoracic iron overload was positively correlated with the risk of developing HCC [7, 8]. Recently, some studies demonstrated that patients with thalassemia and hereditary hemochromatosis, which include liver iron overload, have a high risk for developing HCC [27–29]. HCC patients with portal iron overload have a considerably lower 5-year overall survival rate than those with negative portal iron score [30, 31]. Therefore, iron reduction therapy maybe a promising adjuvant therapy for treating HCC. Previously, our studies indicated that DP significantly inhibited the proliferation of HCC cells. In the present research, we verified that DP decreased labile iron in HepG2 and Huh7 cells and the iron depositions were considerably reduced in tumor tissues of mice bearing Hepa1-6 and H22 tumors compared with the control group after treatment with DP.

Systemic iron homeostasis is regulated by the hepcidin-ferroportin axis under normal physiological conditions, through suppressing iron absorption from the duodenum and iron egress from macrophages and hepatocytes [32, 33]. Ferroportin is the only known cellular iron exporter. The primary molecular action of hepcidin on regulating iron metabolism lies in hepcidin binding and inducing the degradation of ferroportin. As previously reported, our results confirmed that the level of hepcidin in tumor tissues was higher than that in adjacent nontumor tissues on the basis of GSE57957 dataset analysis and IHC staining of HCC tumor tissues. In the current study, we also demonstrated that following DP treatment, the level of hepcidin was downregulated in vitro and in vivo, which may be one of the reasons why DP diminished tumor iron burden and inhibited tumor growth.

Hepcidin transcription is regulated by BMP/SMAD and JAK/STAT pathways in response to inflammatory mediators and the erythropoietic pathway. The JAK/STAT signaling pathway is important in inflammation-induced hepcidin expression [34]. In this work, the RNA-seq data revealed that DP altered the JAK/STAT signaling pathway in HepG2 cells. Western blot results showed that DP administration markedly downregulated the levels of p-JAK2 and p-STAT3 in HepG2 cells. Given that IL-6 plays a key role in regulating inflammatory hepcidin expression by activating STAT3 [35, 36], we examined the roles of DP in the expression of JAK2, p-JAK2, STAT3, and p-STAT3 in HepG2 cells treated with IL-6. The data indicated that pretreatment of HepG2 cells with IL-6 significantly recovered the protein levels of p-JAK2 and p-STAT3. Thus, the suppression of IL-6-induced JAK-STAT signaling pathway may be a possible mechanism involved in DP inhibiting hepcidin expression.
To conclude, we for the first time showed that DP regulated iron burden in hepatoma cells and grafted tumors by decreasing hepcidin expression in vitro and in vivo. The mechanism of DP in decreasing hepcidin expression relies on the suppression of IL-6-induced JAK/STAT signaling pathway. Therefore, our studies provide a novel insight into the anticancer effects of DP on HCC. Collectively, these findings highlighted DP as an innovative candidate for the treatment of HCC.

**Data Availability**

The data used to support the findings of this study are included within the article.

**Conflicts of Interest**

The authors declare no competing financial interests.

**Authors’ Contributions**

FR and JL designed the experiments, and FR and TZ wrote the manuscript. JL, KW, YY, SY, and SM carried out the experiments and analyzed the data.

**Acknowledgments**

This work was supported by the Major Science and Technology Project of Xinxiang City (No. ZD2020005), National Innovation and Entrepreneurship Training Program for College Students (No. 202010472013), Young Teachers Training Projects of Universities in Henan Province (2018GGJS103), Xinxiang Programs for Science and Technology Development (No. GG2019005), and Henan Provincial Medical Science and Technology Research Project (No. SB201901064t).

**References**

[1] L. Wang and F. S. Wang, “Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges,” *Hepatology international*, vol. 13, no. 5, pp. 521–533, 2019.

[2] R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2013,” *CA: a cancer journal for clinicians*, vol. 63, no. 1, pp. 11–30, 2013.

[3] J. B. Porter, T. de Witte, M. D. Cappellini, and N. Gattermann, “New insights into transfusion-related iron toxicity: implications for the oncologist,” *Critical reviews in oncology/hematology*, vol. 99, pp. 261–271, 2016.

[4] S. Zhang, Y. Chen, W. Guo et al., “Disordered hepcidin-ferroportin signaling promotes breast cancer growth,” *Cellular signalling*, vol. 26, no. 11, pp. 2539–2550, 2014.

[5] L. M. Bystrom and S. Rivella, “Cancer cells with iron in the fire,” *Free radical biology & medicine*, vol. 79, pp. 337–342, 2015.

[6] N. Funakoshi, I. Chaze, A. S. Alary et al., “The role of genetic factors in patients with hepatocellular carcinoma and iron overload - a prospective series of 234 patients,” *Liver International*, vol. 36, no. 5, pp. 746–754, 2016.

[7] T. Furutani, K. Hino, M. Okuda et al., “Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein,” *Gastroenterology*, vol. 130, no. 7, pp. 2087–2098, 2006.

[8] M. C. Kew, “Hepatic iron overload and hepatocellular carcinoma,” *Liver cancer*, vol. 3, no. 1, pp. 31–40, 2014.

[9] I. H. Kim, J. H. Moon, S. N. Lim et al., “Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload,” *Transfusion*, vol. 55, no. 7, pp. 1613–1620, 2015.

[10] V. Corce, S. G. Gouin, S. Renaud, F. Gaboriau, and D. Deniaud, “Recent advances in cancer treatment by iron chelators,” *Bioorganic & medicinal chemistry letters*, vol. 26, no. 2, pp. 251–256, 2016.

[11] X. Yan, Y. Yu, P. Ji, H. He, and C. Qiao, “Antitumor activity of endoperoxide-iron chelator conjugates-design, synthesis and biological evaluation,” *European journal of medicinal chemistry*, vol. 102, pp. 180–187, 2015.

[12] V. Sangkhae and E. Nemeth, “Regulation of the iron homeostatic hormone hepcidin,” *Advances in nutrition*, vol. 8, no. 1, pp. 126–136, 2017.

[13] G. Rishi, D. F. Wallace, and V. N. Subramaniam, “Hepcidin: regulation of the master iron regulator,” *Bioscience Reports*, vol. 35, no. 3, 2015.

[14] B. Zhao, R. Li, G. Cheng et al., “Role of hepcidin and iron metabolism in the onset of prostate cancer,” *Oncology letters*, vol. 15, no. 6, pp. 9953–9958, 2018.

[15] L. Tesfay, K. A. Clausen, J. W. Kim et al., “Hepcidin regulation in prostate and its disruption in prostate cancer,” *Oncology research*, vol. 75, no. 11, pp. 2254–2263, 2015.

[16] T. M. Yalovenko, I. M. Todor, N. Y. Lukianova, and V. F. Chekhun, “Hepcidin as a possible marker in determination of malignancy degree and sensitivity of breast cancer cells to cytostatic drugs,” *Experimental oncology*, vol. 38, no. 2, pp. 84–88, 2016.

[17] M. Hara, M. Ando, K. Tsuchiya, and K. Nitta, “Serum hepcidin-25 level linked with high mortality in patients with non-Hodgkin lymphoma,” *Annals of hematology*, vol. 94, no. 4, pp. 603–608, 2015.

[18] J. J. Hin Tang, D. K. Hao Thng, J. J. Lim, and T. B. Toh, “JAK/STAT signaling in hepatocellular carcinoma,” *Hepatic Oncology*, vol. 7, no. 1, 2020.

[19] T. Han, Y. Wan, J. Wang et al., “Set7 facilitates hepatitis C virus replication via enzymatic activity-dependent attenuation of the IFN-related pathway,” *Journal of Immunology*, vol. 194, no. 6, pp. 2757–2768, 2015.

[20] B. D. Maliken, J. E. Nelson, and K. V. Kowdley, “The hepcidin circuits act: balancing iron and inflammation,” *Hepatology*, vol. 53, no. 5, pp. 1764–1766, 2011.

[21] W. Chen, H. Fan, R. Liang, R. Zhang, J. Zhang, and J. Zhu, “Taraxacum officinale extract ameliorates dextran sodium sulphate-induced colitis by regulating fatty acid degradation and microbial dysbiosis,” *Journal of cellular and molecular medicine*, vol. 23, no. 12, pp. 8161–8172, 2019.

[22] D. Jeon, S. J. Kim, and H. S. Kim, “Anti-inflammatory evaluation of the methanolic extract of *Taraxacum officinale* in LPS-stimulated human umbilical vein endothelial cells,” *BMC complementary and alternative medicine*, vol. 17, no. 1, 2017.

[23] C. Nguyen, A. Mehadli, K. Baskaran, S. Grewal, A. Pupulin, and I. Ruvinov, “Dandelion Root and Lemongrass Extracts Induce Apoptosis, Enhance Chemotherapeutic Efficacy, and Reduce Tumour Xenograft Growth In Vivo in Prostate
Cancer,” Evidence-based complementary and alternative medicine : eCAM, 2019, article 2951428.

[24] G. Rehman, M. Hamayun, A. Iqbal et al., “Effect of methanolic extract of dandelion roots on cancer cell lines and AMP-activated protein kinase pathway,” Frontiers in pharmacology, vol. 8, 2017.

[25] H. Zhu, H. Zhao, L. Zhang et al., “Dandelion root extract suppressed gastric cancer cells proliferation and migration through targeting IncRNA-CCAT1,” Biomedicine & Pharmacotherapy, vol. 93, pp. 1010–1017, 2017.

[26] F. Ren, J. Li, X. Yuan et al., “Dandelion polysaccharides exert anticancer effect on hepatocellular carcinoma by inhibiting PI3K/AKT/mTOR pathway and enhancing immune response,” Journal of Functional Foods, vol. 55, pp. 263–274, 2019.

[27] M. Marsella and P. Ricchi, “Thalassemia and hepatocellular carcinoma: links and risks,” Journal of blood medicine, vol. 10, pp. 323–334, 2019.

[28] A. Flores and J. A. Marrero, “Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics,” Clinical Medicine Insights Oncology, vol. 8, pp. 71–76, 2014.

[29] A. Nowak, R. S. Giger, and P. A. Krayenbuehl, “Higher age at diagnosis of hemochromatosis is the strongest predictor of the occurrence of hepatocellular carcinoma in the Swiss hemochromatosis cohort: a prospective longitudinal observational study,” Medicine, vol. 97, no. 42, article e12886, 2018.

[30] J. W. Chung, E. Shin, H. Kim et al., “Hepatic iron overload in the portal tract predicts poor survival in hepatocellular carcinoma after curative resection,” Liver International, vol. 38, no. 5, pp. 903–914, 2018.

[31] Y. Wei, W. Ye, and W. Zhao, “Serum iron levels decreased in patients with HBV-related hepatocellular carcinoma, as a risk factor for the prognosis of HBV-related HCC,” Frontiers in Physiology, vol. 9, 2018.

[32] D. F. Wallace, “The regulation of iron absorption and homeostasis,” The Clinical biochemist Reviews, vol. 37, no. 2, pp. 51–62, 2016.

[33] S. Guo, D. M. Frazer, and G. J. Anderson, “Iron homeostasis: transport, metabolism, and regulation,” Current Opinion in Clinical Nutrition & Metabolic Care, vol. 19, no. 4, pp. 276–281, 2016.

[34] C. K. Chang, X. Zhang, C. Xiao, S. C. Gu, and X. Li, “Research advances of hepcidin expression and its regulation mechanism,” Zhongguo Shi Yan Xue Ye Xue Za Zhi, vol. 20, no. 4, pp. 1030–1033, 2012.

[35] I. Stoian, B. Manolescu, V. Atanasiu, O. Lupescu, and C. Busu, “IL-6 - STAT-3 - hepcidin: linking inflammation to the iron metabolism,” Revue roumaine de medecine interne, vol. 45, no. 3, pp. 305–309, 2007.

[36] A. E. Armitage, L. A. Eddowes, U. Gileadi et al., “Hepcidin regulation by innate immune and infectious stimuli,” Blood, vol. 118, no. 15, pp. 4129–4139, 2011.